Drugs / AAVB-081
AAVB-081
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06591793 | Jul 2024 → Jul 2025 overdue | Usher syndrome type 1B | AAVantgarde Bio Srl | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AAVB-081 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06591793 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “Dual AAV8.MYO7A, AAVB-081” NCT06591793 ↗ |
| Target | MYO7A | “Dual AAV8.MYO7A, AAVB-081” NCT06591793 ↗ |